19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of HLX04-O (proposed bevacizumab biosimilar) in the treatment of...
Pearce IP BioBlast®: w/e 23 July 2021
read more
Blockchain technology gets a nod as patentable subject matter
Advanced New Technologies Co., Ltd. [2021] APO 29
Date: 21 July 2021Forum: Australian Patent OfficeDelegate: Ranganath Subbarayan Background Australian Patent Application 2018243625 (Application) in the name of Advanced New...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which measures adalimumab levels in blood. The test is able to return a...
Pearce IP BioBlast®: w/e 09 July 2021
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar darbepoetin alfa). Under the agreement, Chong Kun Dang will...
Let the applicant beware!
Misrepresentations are not just limited to examples
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe, significant differences remain. This means that patent practitioners...
Pearce IP BioBlast®: w/e 02 July 2021
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its supplemental New Drug Application for Tyvyt® (sintilimab) in...
The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101, which confirmed that a method of...
Pearce IP celebrates milestone with IAM Patent Ranking
Litigation and Prosecution teams & Leaders ranked among Australia's best
Pearce IP is proud to announce that our team has once again been ranked among the best patent practitioners in Australia by IAM Patent 1000. Both our litigation and prosecution...
Sisters are doin’ it for themselves: female inventors more likely to invent for women
A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent female-focused inventions, but a lack of majority female inventor...
Words matter – Specification guides claim construction
Caffitaly System S.P.A. v One Collective Group Pty Ltd [2021] FCAFC 118
Date: 30 June 2021Court: Full Court of the Federal Court of AustraliaJudges: Yates, Moshinsky and Burley JJ Background The case concerns Australian Patents 2003200627 (627...
Pearce IP announced as finalist for Lawyers Weekly Australian Law Awards 2021 “Intellectual Property Team of the Year”
Pearce IP is proud to announce that our team of patent and trademark lawyers and attorneys has been selected as a finalist for the Intellectual Property Team of the Year 2021 in...
Pearce IP BioBlast®: w/e 25 June 2021
23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab under Priority Review. Genentech is seeking approval for its...
Pearce IP Patent Expert Honoured by MIP Patent Star 2021 Award
Following our recent announcement that Principal Naomi Pearce (Patent Star 2021) was honoured with a Managing IP (MIP) Patent Star 2021 awards, Pearce IP’s Special Counsel Patent...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full Court of the Federal Court confirmed in Ariosa Diagnostics,...
Correspondence lost to spam filter justifies extension of time
QIP Nominees Pty Ltd v Delinia, Inc. [2021] APO 24
Date: 22 June 2021Forum: Australian Patent OfficeDelegate: Xavier Gisz Background As part of the Raising the Bar amendments introduced to the Patents Act 1990 (Cth) in 2013,...
Pearce IP BioBlast®: w/e 18 June 2021
10 June 21 | The UK's NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the treatment of moderate rheumatoid arthritis on the NHS....
Pearce IP BioBlast®: w/e 11 June 2021
07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada. Remsima SC® is indicated for the treatment of rheumatoid arthritis. 07 Jun 21 | Merck...
Patent term extension alert: Australian Patent Office scorched by the Federal Court!
Common sense prevails in new interpretation of pharmaceutical extension of term legislation
In September 2020, Pearce IP reported on a significant Australian Patent Office decision, which held that a patent term extension (PTE) request must be based on the first...
Pearce IP practitioner honoured by MIP as IP Stars 2021
Pearce IP is proud that its patent practitioners feature again in the Managing IP Awards 2021. Congratulations to Naomi Pearce, Principal Lawyer, Patent Attorney and Trade Mark...
Australian Patent system review: an ineffectual hand-waving exercise?
A missed opportunity to introduce an alternative second-tier patent system!
Pearce IP recently reported on recommendations made by an independent review into the Australian patent system to overhaul the way in which patent litigation proceeds in...
Common sense prevails in new interpretation of pharmaceutical extension of terms
Ono Pharmaceutical Co, Ltd v Commissioner of Patents [2021] FCA 643
Date: 11 June 2021Court: Federal Court of AustraliaJudge: Beach J Background Under Australian law, patents that cover certain pharmaceutical inventions are eligible for an...
Sticking the knife in – owner of scalpel removal device patent survives entitlement attack
Michael Sinnott v Aunex Pty Ltd [2021] APO 23
Date: 08 June 2021 Forum: Australian Patent Office Delegate: Felix White Background This case concerned a dispute as to inventorship of an apparatus for detaching surgical...
Pearce IP BioBlast®: w/e 04 June 2021
31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald. Citing ‘industry sources’ and a Celltrion official, the...
CRISPR – the application of the wrong inventive step test by the Patent Office means a CRISPR patent application is upheld
JH Corporate Services Pty Ltd v Sigma-Aldrich Co. LLC [2021] APO 22
Date: 02 June 2021Forum: Australian Patent OfficeDelegate: Damian Triffett Background In June 2021, the Australian Patent Office handed down a much-anticipated CRISPR decision,...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.